Cantor Fitzgerald’s Grace Therapeutics GRCE Stock Holding History

Cantor Fitzgerald’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$227K	Buy	+100,000	New	+$277K	﹤0.01%	315

Other funds holding GRCE

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Cantor Fitzgerald's GRCE Position: Q2 2026 in Review

Cantor Fitzgerald opened a new position in Grace Therapeutics (GRCE) in Q2 2026: 100,000 shares worth $227K. The stake represents ﹤0.01% of the portfolio and ranks #315 among its holdings.

31 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

Cantor Fitzgerald held 100,000 shares of Grace Therapeutics worth $227K as of Q2 2026.
Grace Therapeutics was a new Cantor Fitzgerald position in Q2 2026.
Grace Therapeutics made up ﹤0.01% of Cantor Fitzgerald's portfolio in Q2 2026, its #315 holding.
31 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Cantor Fitzgerald's 13F filing for Q2 2026, filed 14 Aug 2026.